Investor Presentation

06th November 2026 To To The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: SAILIFE BSE Scrip code: 544306 Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”). Sub: Investor Presentation on the Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026. Referring to our latter dated 19th October 2026 and pursuant to Regulation 30 of SEBI Listing Regulations we are enclosing herewith the Investor Presentation on Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026. The presentation will be used during the Earnings Conference Call scheduled to be held on Friday, 06th November 2026 at 11:00 A.M. (IST). Further, the above-mentioned presentation is also available on the Website of the Company on following path: https://sailife.com/#> Investors> Financial Information> FY 2027> Earnings Presentation> Q2> Download (https://sailife.com/financial-information/). Kindly take the above information on your record. Thanking you. Yours sincerely, For Sai Life Sciences Limited Runa Karan Company Secretary & Compliance Officer Membership No. A13721 Encl.: As Above Sai Life Sciences Limited (CIN: L24110TG1999PLC030970) Corporate office Registered office Contact us T: +91 40 6815 6000, # L4-01 & 02, SLN Terminus, Survey Plot No. DS-7, IKP Knowledge Park, Turkapally F: +91 40 6815 6199 #133, Gachibowli Miyapur Road, (V), Shameerpet Mandal, Medchal-Malkajgiri E: info@sailife.com Gachibowli, Hyderabad – 500032, (Dist), Hyderabad -500078, Telangana, India. W: www.sailife.com Telangana, India. Sai Life Sciences Investor Presentation November 05, 2026 1 All rights reserved © 2026 Sai Life Sciences Limited Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements", These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. 2 All rights reserved © 2026 Sai Life Sciences Limited Q2 FY27 was a strong quarter for Sai, with continued business momentum and progress across our key strategic priorities. We see growing traction with global pharmaceutical companies, increasing adoption of our integrated outsourcing model, and continued progress in building the capacity and capabilities required to support customers over the long term. Importantly, we are seeing customer engagements evolve from individual projects into larger, more strategic relationships spanning discovery, development and manufacturing. Krishna Kanumuri MD & CEO 33 All rights reserved © 2026 Sai Life Sciences Limited We are pleased to report a healthy performance this quarter, with revenue growing by 23% year- on-year. The performance was broad-based, with both CRO and CDMO delivering healthy growth, while EBITDA margins stood at 28%. We continue to expect a stronger second half, supported by the progression of our development and commercial pipeline and the ramp-up of new capacity. Our capacity and capability expansion programme remains on track with a total of ₹621 crore invested in H1 FY27. ” Siva Chittor Whole-time Director & CFO 44 All rights reserved © 2026 Sai Life Sciences Limited Executive Summary 5 All rights reserved © 2026 Sai Life Sciences Limited 5 All rights reserved © 2026 Sai Life Sciences Limited H1 FY27 Half-yearly Snapshot ₹ 1,213 Cr ₹ 893 Cr ₹ 335 Cr ₹ 172 Cr Revenue Material Margin EBITDA PAT 17% YoY 19% YoY 19% YoY 19% YoY 62 % 38 % ₹ 621 Cr CDMO Revenue Mix CRO Revenue Mix Capex Incurred 6 All rights reserved © 2026 Sai Life Sciences Limited Q2 FY27 Quarterly Snapshot ₹ 659 Cr ₹ 484 Cr ₹ 187 Cr ₹ 98 Cr Revenue Material Margin EBITDA PAT 23% YoY 22% YoY 20% YoY 17% YoY 64 % 36% ₹ 358 Cr 67 % CDMO Revenue Mix CRO Revenue Mix Capex Incurred Capacity Utilization 7 All rights reserved © 2026 Sai Life Sciences Limited Consolidated Financial Highlights (Half Yearly) Revenue (₹Cr) Material Margin (₹Cr) & Margin (%) EBITDA* (₹Cr) & Margin (%) PAT (₹Cr) & Margin (%) 1,213 73% 74% 27% 28% 14% 14% 1,034 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 17% 19% 19% 19% YoY Growth YoY Growth YoY Growth YoY Growth * including forex 8 All rights reserved © 2026 Sai Life Sciences Limited Consolidated Financial Highlights (Quarterly) Revenue (₹Cr) Material Margin (₹Cr) & Margin (%) EBITDA* (₹Cr) & Margin (%) PAT (₹Cr) & Margin (%) 659 74% 73% 29% 16% 15% 537 397 84 98 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 23% 22% 20% 17% YoY Growth YoY Growth YoY Growth YoY Growth * including forex 9 All rights reserved © 2026 Sai Life Sciences Limited Business Updates Commenced operations with our first end-to-end integrated collaboration that we had onboarded last quarter; expected to be fully functional in Q3 10 All rights reserved © 2026 Sai Life Sciences Limited Business Updates • Commenced operations with our first end-to-end integrated collaboration that we had onboarded last quarter; expected to be fully functional in Q3 • Converted another large pharma relationship into a similar strategic engagement • Working on expanding the integrated outsourcing model with other large pharma – discussions underway with few more companies • Added one molecule to late phase pipeline; one molecule advanced from late phase to commercial • Capex spend for 6M FY27 was Rs. 621 Crores (Q2 at Rs. 358 Crores); On track for the overall capex projection of Rs. 1,100 to 1,300 Crores • Unit 2 and Unit 4 received Zero Waste to Landfill Platinum certification, with over 95% of waste diverted from landfills • Certified Great Place To Work® for 2026–27 11 All rights reserved © 2026 Sai Life Sciences Limited Company Overview 12 All rights reserved © 2026 Sai Life Sciences Limited 12 All rights reserved © 2026 Sai Life Sciences Limited Sai Life Sciences: At a Glance Integrated CRDMO Outsourcing Offer complete Contract Research, partner to services from Development and pharma drug discovery to Manufacturing innovators manufacturing Organization 27 Years Global Partner Expansive Innovation-Led of Expertise of Choice Infrastructure Growth Founded in 1999, Sai Life Trusted by 300+ global clients, World-class R&D and Focused investments in next- gen Sciences has transformed into including 19 of the top 25 global manufacturing facilities modalities like Peptides, ADCs an integrated CRDMO, delivering pharma companies across the across Hyderabad, Bidar, and Oligos; empowered by digital value across the pharma lifecycle US, UK, EU, and Japan Manchester, and Boston transformation, automation, and from early discovery to commercial AI/ML to accelerate delivery and manufacturing differentiation 13 All rights reserved © 2026 Sai Life Sciences Limited Key Highlights Fastest growing NSE/BSE 4,400+ 300+ Indian CRDMO Listed on the Indian Total employees* Active customers across Stock Exchanges in US, [Showing first 8,000 characters — download PDF for full document]